Previous 10 | Next 10 |
SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th...
SAN DIEGO , Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
Heron Therapeutics (NASDAQ: HRTX ) announces a successful Type A meeting with the FDA in which alignment was reached to resubmit the New Drug Application or NDA for HTX-011 in Q4. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ......
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced a s...
Shares of Heron Therapeutics (NASDAQ: HRTX) , a small-cap drugmaker, gained 10.7% over the course of July, according to data provided by S&P Global Market Intelligence . The biotech's shares seemingly benefited from a wave of bargain buying last month following the company's sharp pullba...
Quick Take PainReform ( PRFX ) intends to raise $23 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a reformulated pain relief medication for post-operative pain reduction. PRFX management has performed well...
SAN DIEGO , Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some of the most important unmet patient needs, today announc...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Heron Therapeutics' (NASDAQ: HRTX ) Zynrelef (formerly HTX-011), a fixed-dose combination of local anesthetic bupivacaine and nonsteroidal anti-inflammatory med meloxicam, for the ...
SAN DIEGO , July 24, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the...
Evercore ISI has added a healthy 19 stocks in a fresh resumption of its best SMID "core" ideas this month - the research team's very best small and mid-cap stocks. More news on: Cheniere Energy, Inc., WPX Energy, Inc., Chart Industries, Inc., Notable Calls, Healthcare stocks news, Energy s...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...